Simmunome Inc.
2 known investors
Simmunome develops AI-powered disease simulation software for drug development, combining mechanistic modeling with machine learning to predict target efficacy and identify patient responders in clinical trials. The SaaS platform serves biotech and pharmaceutical companies across oncology, neurology, and metabolic disease indications.
Investors · 2
Competitors · 10
by search overlapNucleome7 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Sequome7 shared keywordsSequome uses AI to engineer biological sequences for developing therapeutics, based on its sequence-to-function model called Gene Genie. The company has collaborated with large pharmaceutical firms and Google DeepMind in the drug discovery and biotechnology space.
Cellanome7 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
Immunome7 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Alterome Therapeutics, Inc.6 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Noveome Biotherapeutics5 shared keywordsNoveome is a biopharmaceutical company developing ST266, a multi-targeted secretome biologic containing biologically active proteins and factors aimed at neuroprotection, inflammation modulation, and cell recovery. The company is targeting underserved conditions in ophthalmology, neurology, and dermatology.
Freenome4 shared keywordsFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
Sensome4 shared keywordsSensome develops a microchip-based tissue-sensing technology that embeds bio-impedance sensors into minimally invasive medical devices to give physicians real-time, patient-specific data during procedures. Its lead product, the Clotild Smart Guidewire System, provides real-time blood clot characterization for acute ischemic stroke treatment, with additional applications in lung cancer biopsy and peripheral vascular intervention.
Etiome4 shared keywordsEtiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.
Celldom3 shared keywordsCelldom builds a live single-cell biology platform that uses microwell arrays in standard culture plate format, automated imaging, incubation, and real-time analysis to measure morphology, phenotypes, secreted proteins, gene expression, and cell-cell interactions across more than 100,000 cells per plate. It serves drug discovery and cell manufacturing/QC workflows in the life sciences and biotech sector.
Companies competing with Simmunome Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Simmunome Inc. do?
- Simmunome develops AI-powered disease simulation software for drug development, combining mechanistic modeling with machine learning to predict target efficacy and identify patient responders in clinical trials. The SaaS platform serves biotech and pharmaceutical companies across oncology, neurology, and metabolic disease indications.
- Who are Simmunome Inc.'s investors?
- Simmunome Inc.'s investors include Front Row Ventures, Scale Shift Ventures.